title: [Multiple meningiomas].
abstract: Multiple meningiomas (MMs) or meningiomatosis are defined by the presence of at least 2 lesions that appear simultaneously or not, at different intracranial locations, without the association of neurofibromatosis. They present 1-9 % of meningiomas with a female predominance. The occurrence of multiple meningiomas is not clear. There are 2 main hypotheses for their development, one that supports the independent evolution of these tumors and the other, completely opposite, that suggests the propagation of tumor cells of a unique clone transformation, through cerebrospinal fluid. NF2 gene mutation is an important intrinsic risk factor in the etiology of multiple meningiomas and some exogenous risk factors have been suspected but only ionizing radiation exposure has been proven. These tumors can grow anywhere in the skull but they are more frequently observed in supratentorial locations. Their histologic types are similar to unique meningiomas of psammomatous, fibroblastic, meningothelial or transitional type and in most cases are benign tumors. The prognosis of these tumors is eventually good and does not differ from the unique tumors except for the cases of radiation-induced multiple meningiomas, in the context of NF2 or when diagnosed in children where the outcome is less favorable. Each meningioma lesion should be dealt with individually and their multiple character should not justify their resection at all costs.
authors.affiliation: Service de neurochirurgie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France. Electronic address: lmterrier14@gmail.com.
authors.forename: L-M
authors.initials: LM
authors.lastname: Terrier
authors.affiliation: Service de neurochirurgie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France.
authors.forename: P
authors.initials: P
authors.lastname: François
mesh_terms: D017677:Age Distribution; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D015994:Incidence; D008297:Male; D008577:Meningeal Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000473:pathology / Q000628:therapy; D008579:Meningioma / Q000453:epidemiology / Q000209:etiology / Q000473:pathology / Q000628:therapy; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000453:epidemiology; D009378:Neoplasms, Multiple Primary / Q000453:epidemiology / Q000209:etiology / Q000473:pathology / Q000628:therapy; D009381:Neoplasms, Radiation-Induced / Q000453:epidemiology / Q000209:etiology; D016518:Neurofibromatosis 2 / Q000235:genetics; D059906:Neuroimaging; D019635:Neurosurgical Procedures; D011374:Progesterone; D011379:Prognosis; D012307:Risk Factors; D017678:Sex Distribution
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011374:Progesterone
keywords: Brain tumors; Histoire naturelle; Hormones; Meningioma; Multiple meningiomas; Méningiome; Méningiomes multiples; Natural history; Radiation-induced tumor; Tumeur radio-induite; Tumeurs cérébrales